Flibanserin- Addyi -Improved Sexual Health in Women With Hypoactive Sexual Desire Disorder

MedicalResearch.com Interview with:

Dr. Michael Krychman, MD Executive Director: The Southern California Center for Sexual Health and Survivorship, Medical Director: Sexual Medicine at Hoag Hospital Newport Beach CA Clinical faculty member University of Southern California Los Angeles, CA

Dr. Krychman

Dr. Michael Krychman, MD
Executive Director: The Southern California Center for Sexual Health and Survivorship,
Medical Director: Sexual Medicine at Hoag Hospital Newport Beach CA
Clinical faculty member
University of Southern California
Los Angeles, CA

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: This post hoc analysis pooled data from three 24-week, double-blind, placebo-controlled studies (VIOLET, DAISY, and BEGONIA) of flibanserin in premenopausal women with acquired, generalized HSDD5-7. Patients who received flibanserin 100 mg once daily at bedtime (qhs) or placebo were included in the analysis. The Female Sexual Function Index (FSFI) consists of 19 items across 6 domains. Scores range from 2 to 36. Higher scores indicate better sexual functioning. Scores under 26 indicate sexual dysfunction. Analysis of covariance was used to evaluate changes from the first week to week 24 in the FSFI domain and total scores were compared for flibanserin 100 mg qhs versus placebo. For patients who discontinued study participation prior to week 24, the last postbaseline observation was carried forward (LOCF).

Results found that treatment with flibanserin 100 mg qhs produced statistically significant improvement, relative to placebo, on all domains of the FSFI (desire, arousal, lubrication, orgasm, satisfaction and pain) in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

MedicalResearch.com: What should readers take away from your report?

Response: These results support the original study findings, which showed greater improvement for flibanserin versus placebo on the FSFI desire domain and total scores.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: It’s important for women to know that their sexual concerns could be a true medical condition, and there are treatments and solutions available for them. It is essential that those in the sexual health space further their research into the safe and appropriate prescribing and use of flibanserin, as well as advancing the understanding of female sexual dysfunction (FSD).

MedicalResearch.com: Is there anything else you would like to add?

Response: Women deserve the right for choice. Health Care Providers need to be educated on safe, effective treatments for HSDD, so that they may help their patients who are suffering in silence to learn about potential options. Medical intervention is not for every woman, and individualized treatment paradigms that incorporate both medical and psychological interventions are important to have in your armamentarium for the treatment of hypoactive sexual desire disorder .

Dr. Krychman is a consultant for Valeant Pharmaceuticals.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

AUA 2017 abstract: Sunday, May 7, 2017:
Effect of Flibanserin on Sexual Functioning: An Analysis of Female Sexual Function Index Domains
Krychman, Michael L. MD, MPH; Yuan, James MD, PhD, MBA; Barbour, Krista PhD, MPH; Kissling, Rob MD; Derogatis, Leonard R. MD
Obstetrics & Gynecology: May 2017
doi: 10.1097/01.AOG.0000514926.52168.76

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

 

Leave a Reply

Your email address will not be published.